Phase I Trial of Oral Fenretinide in Children With High-Risk Solid Tumors: A Report From the Children's Oncology Group (CCG 09709)
- 20 July 2006
- journal article
- pediatric oncology
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 24 (21), 3423-3430
- https://doi.org/10.1200/jco.2005.03.9271
Abstract
Purpose To determine the maximal tolerated dosage (MTD) of oral fenretinide given as intact capsules for 7 days, repeated every 21 days, in children with high-risk solid tumors. Methods Children 21...Keywords
This publication has 40 references indexed in Scilit:
- Fenretinide Cytotoxicity for Ewing’s Sarcoma and Primitive Neuroectodermal Tumor Cell Lines Is Decreased by Hypoxia and Synergistically Enhanced by Ceramide ModulatorsCancer Research, 2004
- Ceramide synthesis and metabolism as a target for cancer therapyCancer Letters, 2004
- Ceramide Signaling in Fenretinide-induced Endothelial Cell ApoptosisPublished by Elsevier ,2002
- Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trialsBiostatistics, 2001
- Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic AcidNew England Journal of Medicine, 1999
- Differential Effects of Retinoic Acid (RA) andN-(4-Hydroxyphenyl)retinamide (4-HPR) on Cell Growth, Induction of Differentiation, and Changes in p34cdc2, Bcl-2, and Actin Expression in the Human Promyelocytic HL-60 Leukemic CellsBiochemical and Biophysical Research Communications, 1996
- Growth Inhibition and Induction of Apoptosis by Fenretinide in Small-Cell Lung Cancer Cell LinesJNCI Journal of the National Cancer Institute, 1995
- Controlled clinical trials with fenretinide in breast cancer, basal cell carcinoma and oral leukoplakiaJournal of Cellular Biochemistry, 1995
- Neuroblastoma cell apoptosis induced by the synthetic retinoid N‐(4‐hydroxyphenyl)retinamideInternational Journal of Cancer, 1994
- Tolerability of the synthetic retinoid fenretinide® (HPR)European Journal of Cancer and Clinical Oncology, 1989